



MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025

Conference call and webcast scheduled for Wednesday, March 19th at 8:30 a.m. Eastern Time

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025.

Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.

Dial-in and call details are as follows:

Conference Call & Webcast Details

Toll-Free: 1-833-630-1956

Israel: 1-80-921-2373

International: 1-412-317-1837

Webcast: [Click HERE](#)

To access the call, participants should dial the applicable telephone number above **at least 5 minutes** prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound's first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the currently available \$375+ million drug for wound debridement, presenting a unique opportunity for significant market growth.

For more information visit www.mediwound.com and follow us on [LinkedIn](#).

MediWound Contacts:

Hani Luxenburg

Chief Financial Officer

MediWound Ltd.

ir@mediwound.com

Daniel Ferry

Managing Director

LifeSci Advisors, LLC

daniel@lifesciadvisors.com

Media Contact:

Ellie Hanson

FINN Partners for MediWound

ellie.hanson@finnpartners.com

+1-929-588-2008